x
ABILITY is the flagship Brain-Computer Interface (BCI) project developed at the Wyss Center. After eight years of intensive research and development initiated under the leadership of Professor John Donoghue, a founding pioneer in the world of BCI, the project has achieved groundbreaking advances in neural signal processing and therapeutic applications.
In January 2025 ABILITY Neurotech SA spun off from the Wyss Center as an independent, Swiss-based start up. It is Europe’s first company offering a fully implantable BCI device designed for people living with debilitating neurological conditions who have lost their capacity to communicate or move.
ABILITY Neurotech represents a significant step towards clinical applications and commercialization of this revolutionary BCI technology. The ABILITY BCI system offers a highly advanced capability to record, transmit, analyze, and stimulate the brain, restoring fundamental functions and improving the quality of life for patients.
This versatile platform is poised to significantly impact millions of patients suffering from incapacitating neurological disorders, including stroke, spinal cord injuries, and amyotrophic lateral sclerosis (ALS).
